These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33721435)

  • 21. Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer.
    Stock RG; Stone NN
    Brachytherapy; 2002; 1(1):2-10. PubMed ID: 15062181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Three-dimensional conformal therapy versus standard radiation therapy in localized carcinoma of prostate: an update.
    Perez CA; Michalski JM; Mansur D; Lockett MA
    Clin Prostate Cancer; 2002 Sep; 1(2):97-104. PubMed ID: 15046700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A systematic overview of radiation therapy effects in prostate cancer.
    Nilsson S; Norlén BJ; Widmark A
    Acta Oncol; 2004; 43(4):316-81. PubMed ID: 15303499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study).
    Hwang K; Kim TM; Park CK; Chang JH; Jung TY; Kim JH; Nam DH; Kim SH; Yoo H; Hong YK; Kim EY; Lee DE; Joo J; Kim YJ; Choe G; Choi BS; Kang SG; Kim JH; Kim CY
    Cancer Res Treat; 2020 Apr; 52(2):505-515. PubMed ID: 31671938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Clinical Effects of Temozolomide Single Agent and Combined Doxorubicin in the Treatment of Glioma.
    Liu Y; Chen L
    J Healthc Eng; 2022; 2022():7995385. PubMed ID: 35345663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Safety and efficacy of three-dimensional conformal radiotherapy combined with temozolomide in treatment of diffuse brainstem gliomas].
    Fang HH; Nie Q; Kang JB; Li FM; Cai CL
    Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):707-9. PubMed ID: 22340055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Three-dimensional conformal therapy or standard irradiation in localized carcinoma of prostate: preliminary results of a nonrandomized comparison.
    Perez CA; Michalski JM; Purdy JA; Wasserman TH; Williams K; Lockett MA
    Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):629-37. PubMed ID: 10837945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Variations in international prostate symptom scores, uroflowmetric parameters, and prostate volume after (125)I permanent brachytherapy for localized prostate cancer.
    Tanaka N; Fujimoto K; Hirao Y; Asakawa I; Hasegawa M; Konishi N
    Urology; 2009 Aug; 74(2):407-11. PubMed ID: 19376570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
    Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of the impact of isotope ((125)I vs. (103)Pd) on toxicity and biochemical outcome after interstitial brachytherapy and external beam radiation therapy for clinically localized prostate cancer.
    Kollmeier MA; Pei X; Algur E; Yamada Y; Cox BW; Cohen GN; Zaider M; Zelefsky MJ
    Brachytherapy; 2012; 11(4):271-6. PubMed ID: 22192495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preliminary results of three-dimensional conformal radiotherapy as salvage treatment for a rising prostate-specific antigen level postprostatectomy.
    Wilder RB; Hsiang JY; Ji M; Earle JD; de Vere White R
    Am J Clin Oncol; 2000 Apr; 23(2):176-80. PubMed ID: 10776980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.
    Fine HA; Figg WD; Jaeckle K; Wen PY; Kyritsis AP; Loeffler JS; Levin VA; Black PM; Kaplan R; Pluda JM; Yung WK
    J Clin Oncol; 2000 Feb; 18(4):708-15. PubMed ID: 10673511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas: long-term analysis of a phase II study.
    Balducci M; D'Agostino GR; Manfrida S; De Renzi F; Colicchio G; Apicella G; Mangiola A; Fiorentino A; Frascino V; Mantini G; De Bari B; Pompucci A; Valentini V; Anile C; Cellini N
    J Neurooncol; 2010 Mar; 97(1):95-100. PubMed ID: 19705066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Matched-cohort analysis of patients with prostate cancer followed with observation or treated with three-dimensional conformal radiation therapy.
    Kramer NM; Horwitz EM; Uzzo RG; Hanlon AL; Hanks GE
    BJU Int; 2004 Jul; 94(1):59-62. PubMed ID: 15217432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Outcomes and predictors of T3a prostate cancer treated by permanent interstitial brachytherapy combined with external radiotherapy and hormone therapy].
    Mai Z; Yan W; Li H; Zhou Y; Zhou Z; Chen J
    Zhonghua Wai Ke Za Zhi; 2014 Oct; 52(10):765-70. PubMed ID: 25573217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long term follow-up and outcomes in adult patients with thalamic gliomas.
    Li Z; Wu H; Wu B; Lyu J; Liu Y; Tang C; Hua W; Hu S; Wang Y; Zhang Y
    Clin Neurol Neurosurg; 2020 Aug; 195():105888. PubMed ID: 32450499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recurrent gliomas: comparison of computed tomography (CT)-guided 125I seed implantation therapy and traditional radiochemotherapy.
    Hu X; Qiu H; Zhang L; Zhang W; Ma Y; Qiao Z; Chen D; Han J; Duan G; Zhang F
    Cancer Biol Ther; 2012 Aug; 13(10):840-7. PubMed ID: 22797010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II Study of the Efficacy and Safety of High-dose Pemetrexed in Combination with Cisplatin
    He Q; Bi X; Ren C; Wang Y; Zou P; Zhang H; Chi N; Xiu C; Wang Y; Tao R
    Anticancer Res; 2017 Aug; 37(8):4711-4716. PubMed ID: 28739776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.